Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 46

Sort by

Sort Order Select

Journal Articles

Dual targeting of CD19 and CD22 with bicistronic CAR-T cells in patients with relapsed/refractory large B-cell lymphoma

Blood (2023) 141 (20): 2470–2482.

https://doi.org/10.1182/blood.2022018598

Published: 2023

Includes: Supplemental data

Journal Articles

Metabolic Tumor Volume Predicts Outcomes in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Treated with Loncastuximab Tesirine in the Lotis-2 Trial

Blood (2022) 140 (Supplement 1): 6650–6652.

https://doi.org/10.1182/blood-2022-162758

Published: 2022

Journal Articles

Long Term Follow-up of International Randomised Phase 3 Study of Rituximab Versus a Watch and Wait Approach for Patients with Asymptomatic, Low Tumour Burden Follicular Lymphoma Shows Rituximab Is Highly Effective at Delaying Time to New Treatment without Detrimental Impact Following Next Line of Therapy

Michael Northend, William Wilson, Laura Clifton-Hadley, Zaynab Rana, Tanya-Louise Martin, Moya Young, Fiona Miall, David Cunningham, Jan Walewski, Burhan Ferhanoglu, Amanda Johnston, John F. Seymour, David C. Linch, Kirit M. Ardeshna

Blood (2022) 140 (Supplement 1): 1456–1458.

https://doi.org/10.1182/blood-2022-156790

Published: 2022

Journal Articles

Replacing Procarbazine with Dacarbazine in Escalated Beacopp Dramatically Reduces the Post Treatment Haematopoietic Stem and Progenitor Cell Mutational Burden in Hodgkin Lymphoma Patients with No Apparent Loss of Clinical Efficacy

Blood (2022) 140 (Supplement 1): 1761–1764.

https://doi.org/10.1182/blood-2022-166543

Published: 2022

Journal Articles

Durable Responses from Acalabrutinib in Combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisolone (R-CHOP) As First Line Therapy for Patients with Diffuse Large B-Cell Lymphoma (DLBCL): The Accept Phase Ib/II Single Arm Study

Andrew J Davies, Josh Caddy, Katy McLaughlin, Christopher Wignall, Robert Waugh, Graham P. Collins, Louise Stanton, Geoff N Saunders, Thomas Cummin, Anna Schuh, Kirit M. Ardeshna, Andrew K. McMillan, John Radford, David John Lewis, Adam R Coleman, Gareth Griffiths, Cathy Burton, Sharon Barrans, Peter Johnson

Blood (2022) 140 (Supplement 1): 9478–9479.

https://doi.org/10.1182/blood-2022-163499

Published: 2022

Journal Articles

Real World Escalated Beacopdac Delivers Similar Outcomes to Escalated Beacopp and Superior Outcomes to Response-Adapted (RATHL) ABVD, While Potentially Reducing Toxicity Compared with Escalated Beacopp

Blood (2021) 138 (Supplement 1): 877.

https://doi.org/10.1182/blood-2021-146242

Published: 2021

Journal Articles

Clinical Characteristics and Responses of Patients with Relapsed or Refractory High-Grade B-Cell Lymphoma Treated with Loncastuximab Tesirine in the Lotis-2 Clinical Trial

Juan Pablo Alderuccio, Weiyun Z. Ai, John Radford, Melhem Solh, Kirit M. Ardeshna, Matthew A. Lunning, Brian T. Hess, Pier Luigi Zinzani, Anastasios Stathis, Carmelo Carlo-Stella, Mehdi Hamadani, Brad S. Kahl, David Ungar, Turk Kilavuz, Eric Yu, Yajuan Qin, Paolo F. Caimi

Blood (2021) 138 (Supplement 1): 3575.

https://doi.org/10.1182/blood-2021-148730

Published: 2021

Journal Articles

The Anti-CD19 Antibody-Drug Conjugate Loncastuximab Tesirine Achieved Responses in Patients with Diffuse Large B-Cell Lymphoma Who Relapsed after Anti-CD19 CAR T-Cell Therapy

Paolo F. Caimi, Kirit M. Ardeshna, Erin Reid, Weiyun Z. Ai, Matthew A. Lunning, Jasmine Zain, Melhem Solh, Brad S. Kahl, Mehdi Hamadani

Blood (2021) 138 (Supplement 1): 2489.

https://doi.org/10.1182/blood-2021-153591

Published: 2021

Journal Articles

Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphoma

Mehdi Hamadani, John Radford, Carmelo Carlo-Stella, Paolo F. Caimi, Erin Reid, Owen A. O’Connor, Jay M. Feingold, Kirit M. Ardeshna, William Townsend, Melhem Solh, Leonard T. Heffner, David Ungar, Luqiang Wang, Joseph Boni, Karin Havenith, Yajuan Qin, Brad S. Kahl

Blood (2021) 137 (19): 2634–2645.

https://doi.org/10.1182/blood.2020007512

Published: 2021

Includes: Supplemental data

Journal Articles

Acalabrutinib in Combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisolone (R-CHOP) As First Line Therapy for Patients with Diffuse Large B-Cell Lymphoma (DLBCL): The Accept Phase Ib/II Single Arm Study

Andrew Davies, Josh Caddy, Katy Mercer, Geoff N Saunders, Louise Stanton, Graham P. Collins, MD DPhil, Thomas E C Cummin, MRCP MBBCh BSc, Anna Schuh, MD MRCP, PhD, Kirit M. Ardeshna, Andrew McMillan, John A. Radford, MD FMedSci, David John Lewis, MD, Adam Coleman, Gareth Griffiths, Cathy Burton, MBBChir, MA, MD FRCPath, Sharon Barrans, Peter Johnson, MD FRCP

Blood (2020) 136 (Supplement 1): 38–39.

https://doi.org/10.1182/blood-2020-134546

Published: 2020

Journal Articles

Efficacy and Safety of Loncastuximab Tesirine (ADCT-402) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Paolo F Caimi, Weiyun Z. Ai, Juan Pablo Alderuccio, MD, Kirit M. Ardeshna, Mehdi Hamadani, MD, Brian T. Hess, MD, Brad S. Kahl, MD, John A. Radford, MD FMedSci, Melhem Solh, MD, Anastasios Stathis, MD, Pier Luigi Zinzani, MD, Jay Feingold, David Ungar, Yajuan Qin, Shui He, Carmelo Carlo-Stella, MD

Blood (2020) 136 (Supplement 1): 35–37.

https://doi.org/10.1182/blood-2020-137524

Published: 2020

Journal Articles

Steroid Use, Advanced Stage Disease and ≥3 Lines of Prior Chemotherapy Are Associated with a Higher Risk of Infection Following CD19 CAR T-Cell Therapy for B-NHL: Real World Data from a Large UK Center

Lorna Neill, Strachan C Mackenzie, MBBS, BSc, MRCP, Maria A V Marzolini, William Townsend, MRCP,MDFRCPath, Kirit M. Ardeshna, Kate Cwynarski, Surjo De, Vanya Gant, Lhara Mure, Sara McElduff, Chantelle Hughes, Karl S Peggs, MD PhD, Claire Roddie, PhD MD, Maeve A O'Reilly, MBBCHBAO

Blood (2020) 136 (Supplement 1): 20–21.

https://doi.org/10.1182/blood-2020-138865

Published: 2020

Journal Articles

Phase 1/2 Study of AUTO3 the First Bicistronic Chimeric Antigen Receptor (CAR) Targeting CD19 and CD22 Followed By an Anti-PD1 in Patients with Relapsed/Refractory (r/r) Diffuse Large B Cell Lymphoma (DLBCL): Results of Cohort 1 and 2 of the Alexander Study

Kirit M. Ardeshna, MBBChir, Maria A V Marzolini, Jane Norman, MD, Muhammad Al-Hajj, Simon Thomas, PhD, Jim Faulkner, Ekaterini Kotsopoulou, Martin Pule, MD, Vijay G R Peddareddigari, Nushmia Z Khokhar, Maud Jonnaert, PhD, Robert Chen, MD, Wendy Osborne, MD

Blood (2019) 134 (Supplement_1): 246.

https://doi.org/10.1182/blood-2019-122724

Published: 2019

Journal Articles

Phase 2 Results of the iR 2 Regimen (Ibrutinib, Lenalidomide, and Rituximab) in Patients with Relapsed/Refractory (R/R) Non-Germinal Center B Cell-like (Non-GCB) Diffuse Large B-Cell Lymphoma (DLBCL)

Blood (2019) 134 (Supplement_1): 761.

https://doi.org/10.1182/blood-2019-121521

Published: 2019

Journal Articles

Procarbazine-Free Escalated Beacopdac in Frontline Therapy of Advanced Hodgkin Lymphoma Reduces Red Cell Transfusion Requirements and May Shorten Time to Menstrual Period Recovery Compared to Escalated Beacopp and Appears to be As Efficacious

Blood (2019) 134 (Supplement_1): 1564.

https://doi.org/10.1182/blood-2019-125256

Published: 2019

Journal Articles

Core Biopsies Performed By Experienced Radiologists and Analysed By Expert Haemato-Pathologists Reliably Permit the Rapid and Safe Diagnosis of Lymphoproliferative Diseases and Negate the Need for Excisional Biopsy in Almost All Patients. Experience from 554 Sequential Core Biopsies from a Single Centre

Oliver C Cohen, MBBS, BSc, FRCPath, Max Brodermann, Aoife Dervin, MBBS, BSc, MRCP, Simon Morley, Ian Proctor, Neel Raja, Kirit M. Ardeshna, MA, MD FRCP, FRCPath, William Townsend, MD FRCPath

Blood (2019) 134 (Supplement_1): 4746.

https://doi.org/10.1182/blood-2019-123698

Published: 2019

Journal Articles

Prognostic and Immune-Related Factors for Response to Duvelisib in the Phase 2 DYNAMO TM Clinical Trial in iNHL

Pier Luigi Zinzani, MD, Ian W. Flinn, MD PhD, Carole B. Miller, MD, Scott A. Tetreault, MD, Kirit M. Ardeshna, MBBChir, NgocDiep Le, MD PhD, Jonathan A. Pachter, PhD, Kam Sprott, PhD, Stephanie Lustgarten, PhD, David T. Weaver, PhD, Nina D. Wagner-Johnston, MD

Blood (2018) 132 (Supplement 1): 4167.

https://doi.org/10.1182/blood-2018-99-117903

Published: 2018

Journal Articles

Encouraging Clinical Outcomes for Lymphoma Patients Participating in Early Phase Clinical Trials in the Current Era: A Single Institution and a Global Perspective

Jenny O'Nions, MBBChir, PhD MRCP, FRCPath, Anna Cowley, MBBS, BSc, MRCP, FRCPath, Hakim-Moulay Dehbi, PhD, Dima El-Sharkawi, MBBS BSc FRCPath MD, Shirley D'Sa, MD FRCP, FRCPath, Kirit M. Ardeshna, MA MDFRCP FRCPath, Rakesh Popat, MBBS, BSc, MRCP, FRCPath, PhD, William Townsend, MD FRCPath

Blood (2018) 132 (Supplement 1): 4227.

https://doi.org/10.1182/blood-2018-99-118497

Published: 2018

Journal Articles

The iR 2 Regimen(Ibrutinib, Lenalidomide, and Rituximab) Is Active with a Manageable Safety Profile in Patients with Relapsed/Refractory Non-Germinal Center-like Diffuse Large B-Cell Lymphoma

Blood (2018) 132 (Supplement 1): 402.

https://doi.org/10.1182/blood-2018-99-111163

Published: 2018

Journal Articles

Interim Results from the First-in-Human Clinical Trial of Adct-402 (Loncastuximab Tesirine), a Novel Pyrrolobenzodiazepine-Based Antibody Drug Conjugate, in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

John Radford, MD FRCP, Brad S. Kahl, MD, Mehdi Hamadani, MD, Carmelo Carlo-Stella, MD, Paolo Caimi, MD, Kirit M. Ardeshna, MBBChir, Jay Feingold, MD PhD, Shui He, PhD, Erin Reid, MD, Melhem Solh, MD, Ki-Young Chung, MD, Leonard Heffner, MD, David Ungar, MD, Owen A. O'Connor, MD, PhD

Blood (2018) 132 (Supplement 1): 398.

https://doi.org/10.1182/blood-2018-99-116081

Published: 2018

NARROW

Dual targeting of CD19 and CD22 with bicistronic CAR-T cells in patients with relapsed/refractory large B-cell lymphoma

Metabolic Tumor Volume Predicts Outcomes in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Treated with Loncastuximab Tesirine in the Lotis-2 Trial

Replacing Procarbazine with Dacarbazine in Escalated Beacopp Dramatically Reduces the Post Treatment Haematopoietic Stem and Progenitor Cell Mutational Burden in Hodgkin Lymphoma Patients with No Apparent Loss of Clinical Efficacy

Durable Responses from Acalabrutinib in Combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisolone (R-CHOP) As First Line Therapy for Patients with Diffuse Large B-Cell Lymphoma (DLBCL): The Accept Phase Ib/II Single Arm Study

Real World Escalated Beacopdac Delivers Similar Outcomes to Escalated Beacopp and Superior Outcomes to Response-Adapted (RATHL) ABVD, While Potentially Reducing Toxicity Compared with Escalated Beacopp

Clinical Characteristics and Responses of Patients with Relapsed or Refractory High-Grade B-Cell Lymphoma Treated with Loncastuximab Tesirine in the Lotis-2 Clinical Trial

The Anti-CD19 Antibody-Drug Conjugate Loncastuximab Tesirine Achieved Responses in Patients with Diffuse Large B-Cell Lymphoma Who Relapsed after Anti-CD19 CAR T-Cell Therapy

Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphoma

Acalabrutinib in Combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisolone (R-CHOP) As First Line Therapy for Patients with Diffuse Large B-Cell Lymphoma (DLBCL): The Accept Phase Ib/II Single Arm Study

Efficacy and Safety of Loncastuximab Tesirine (ADCT-402) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Steroid Use, Advanced Stage Disease and ≥3 Lines of Prior Chemotherapy Are Associated with a Higher Risk of Infection Following CD19 CAR T-Cell Therapy for B-NHL: Real World Data from a Large UK Center

Phase 1/2 Study of AUTO3 the First Bicistronic Chimeric Antigen Receptor (CAR) Targeting CD19 and CD22 Followed By an Anti-PD1 in Patients with Relapsed/Refractory (r/r) Diffuse Large B Cell Lymphoma (DLBCL): Results of Cohort 1 and 2 of the Alexander Study

Phase 2 Results of the iR 2 Regimen (Ibrutinib, Lenalidomide, and Rituximab) in Patients with Relapsed/Refractory (R/R) Non-Germinal Center B Cell-like (Non-GCB) Diffuse Large B-Cell Lymphoma (DLBCL)

Procarbazine-Free Escalated Beacopdac in Frontline Therapy of Advanced Hodgkin Lymphoma Reduces Red Cell Transfusion Requirements and May Shorten Time to Menstrual Period Recovery Compared to Escalated Beacopp and Appears to be As Efficacious

Prognostic and Immune-Related Factors for Response to Duvelisib in the Phase 2 DYNAMO TM Clinical Trial in iNHL

Encouraging Clinical Outcomes for Lymphoma Patients Participating in Early Phase Clinical Trials in the Current Era: A Single Institution and a Global Perspective

The iR 2 Regimen(Ibrutinib, Lenalidomide, and Rituximab) Is Active with a Manageable Safety Profile in Patients with Relapsed/Refractory Non-Germinal Center-like Diffuse Large B-Cell Lymphoma

Interim Results from the First-in-Human Clinical Trial of Adct-402 (Loncastuximab Tesirine), a Novel Pyrrolobenzodiazepine-Based Antibody Drug Conjugate, in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only